Findings showed the risk of disease progression or death was reduced by 79% with nivolumab and ipilimumab combination therapy vs chemotherapy (hazard ratio [HR], 0.21 [95% CI, 0.14-0.32]; P ...

The optimal duration of treatment with each drug has yet ... data from the phase II CheckMate 142 trial suggested nivolumab plus ipilimumab provided better outcomes than did single-agent nivolumab.

41.7% with nivolumab/ipilimumab, and 23% with nivolumab). Similar differences existed for clinical to pathologic downstaging after neoadjuvant therapy (46.7%, 41.7%, and 23%). Patients who had a ...

Additional treatment options are needed for patients ... phase 3 CheckMate 8HW trial show significantly longer PFS with nivolumab plus ipilimumab than with chemotherapy (one of two dual primary ...

The EC has approved BMS Opdivo in combination with Yervoy as a first-line treatment for adults with unresectable or advanced ...

Researchers conducting a clinical trial of immunotherapy drugs for people with head and neck squamous cell carcinomas (HNSCCs) found that patients responded better to a combination of two ...

Chronic cutaneous adverse events affected 8% of patients after checkpoint inhibitor therapy in a cohort study, often ...

During a live event, Thach-Giao Truong, MD, moderated a discussion on treating a 78-year-old patient with metastatic melanoma ...

The researchers called for further study to understand the mechanism of the relationship between obesity and ICI outcomes.

Gut microbiota composition may influence the efficacy and safety of chemo-immunotherapy in advanced non-small cell lung cancer. Read now.